Squarepoint
CNTA

Squarepoint’s Centessa Pharmaceuticals CNTA Stock Holding History

Squarepoint’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,900
Closed -$229K – 4564
2025
Q1 		$229K Buy
+15,900
New +$260K ﹤0.01% 3926

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Squarepoint's CNTA Position: Q1 2026 in Review

Squarepoint reduced its Centessa Pharmaceuticals (CNTA) stake by 38% in Q1 2026, selling an estimated $798K and leaving 50,606 shares worth $2.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2181.

Squarepoint first reported a position in CNTA in Q2 2021 and has held it in 8 quarters since. The position peaked at $2.05M in Q4 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Squarepoint held 50,606 shares of Centessa Pharmaceuticals worth $2.01M as of Q1 2026.
  • Squarepoint sold 31,206 Centessa Pharmaceuticals shares in Q1 2026, an estimated $798K.
  • Centessa Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2181 holding.
  • Squarepoint first reported a position in Centessa Pharmaceuticals in Q2 2021 and has held it in 8 quarters since.
  • Squarepoint's Centessa Pharmaceuticals position peaked at $2.05M in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.